» Articles » PMID: 15906341

Prognostic Value of Dynamic MR Imaging for Non-small-cell Lung Cancer Patients After Chemoradiotherapy

Overview
Date 2005 May 21
PMID 15906341
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: To determine the prognostic value of dynamic MRI for non-small-cell lung cancer (NSCLC) patients after chemoradiotherapy.

Materials And Methods: A total of 114 consecutive patients with NSCLC underwent dynamic MRI after chemoradiotherapy. The patients were divided into two groups (local control (n=22) and local failure (n=92)) according to the presence of local recurrence. From the signal intensity-time course curve in each subject, the maximum relative enhancement ratio and slope of enhancement were calculated, and compared between two groups by Student's t-test. To determine the feasible threshold values of both MR indexes for group differentiation, ROC-based positive tests were performed. Finally, the Kaplan-Meier survival curves of each group divided by the adapted threshold value were compared by log-rank test.

Results: The maximum relative enhancement ratio and the slope of enhancement in the local control group were significantly lower than those in the local failure group (P<0.05). Using 0.08/sec as the threshold value of the slope of enhancement, the sensitivity and specificity for differentiation between the two groups were 90.9% and 91.3%, respectively. When the slope of enhancement was adopted for estimation of prognosis after therapy, the mean survival period of the slope of enhancement<or=0.08/sec group was significantly longer than that seen in the group with a slope of enhancement>0.08/sec (P<0.0001).

Conclusion: Dynamic MRI has potential prognostic value for NSCLC patients after chemoradiotherapy.

Citing Articles

Prognostication of overall survival in patients with brain metastases using diffusion tensor imaging and dynamic susceptibility contrast-enhanced MRI.

de Godoy L, Chen Y, Chawla S, Viaene A, Wang S, Loevner L Br J Radiol. 2022; 95(1140):20220516.

PMID: 36354164 PMC: 9733614. DOI: 10.1259/bjr.20220516.


Dynamic contrast-enhanced (DCE) imaging: state of the art and applications in whole-body imaging.

Albano D, Bruno F, Agostini A, Angileri S, Benenati M, Bicchierai G Jpn J Radiol. 2021; 40(4):341-366.

PMID: 34951000 DOI: 10.1007/s11604-021-01223-4.


Dynamic Contrast-enhanced Area-detector CT vs Dynamic Contrast-enhanced Perfusion MRI vs FDG-PET/CT: Comparison of Utility for Quantitative Therapeutic Outcome Prediction for NSCLC Patients Undergoing Chemoradiotherapy.

Seki S, Fujisawa Y, Yui M, Kishida Y, Koyama H, Ohyu S Magn Reson Med Sci. 2019; 19(1):29-39.

PMID: 30880291 PMC: 7067914. DOI: 10.2463/mrms.mp.2018-0158.


SEOM-SERAM-SEMNIM guidelines on the use of functional and molecular imaging techniques in advanced non-small-cell lung cancer.

Fernandez-Perez G, Sanchez-Escribano R, Garcia-Vicente A, Luna-Alcala A, Ceballos-Viro J, Delgado-Bolton R Clin Transl Oncol. 2017; 20(7):837-852.

PMID: 29256154 PMC: 5996017. DOI: 10.1007/s12094-017-1795-y.


Value of intravoxel incoherent motion and dynamic contrast-enhanced MRI for predicting the early and short-term responses to chemoradiotherapy in nasopharyngeal carcinoma.

Hou J, Yu X, Hu Y, Li F, Xiang W, Wang L Medicine (Baltimore). 2016; 95(35):e4320.

PMID: 27583847 PMC: 5008531. DOI: 10.1097/MD.0000000000004320.